Every headline about a GLP-1 trial leads with the same number: percent of body weight lost. Tirzepatide beat semaglutide by this many points. The new pill hit this percentage at 72 weeks. It’s a clean number, and it makes for an easy comparison — which is exactly what a scientific statement published this month argues is the problem.
On September 9, the Endocrine Society published “Obesity Science, Research Gaps, and Opportunities in the New Era of Obesity Medicines” in Endocrine Reviews. A panel led by Dr. Daniel Drucker — one of the researchers whose lab work underlies the GLP-1 drug class in the first place — reviewed more than 200 studies and concluded that the field needs to stop treating percent weight loss as the finish line.
What the statement actually argues
The core claim is narrower than “weight doesn’t matter.” It’s that weight loss percentage, used alone, hides more than it reveals.
Dr. Drucker put it this way in coverage of the statement: for many patients, “there are important outcomes in terms of heart disease, kidney disease, liver disease, arthritis, cognitive function… important simply beyond the number of pounds or kilograms lost.” Two patients can lose the same 15% of body weight and have very different things happen to their blood pressure, their liver, their joints, or their sleep apnea severity. The scale doesn’t distinguish between them.
The panel laid out six research priorities, including:
- Better understanding of how the body defends a given amount of fat mass, and why that makes some weight loss harder to sustain than other weight loss
- Why obesity “manifests differently in individuals” in ways that predict who responds well to a given medication and who doesn’t
- Organ-specific outcomes — cardiovascular, kidney, and liver disease progression — tracked independently of the weight-loss number
- Validated ways to measure whether bone and muscle are preserved during treatment, not just total mass lost
- What actually happens, physiologically, across the different phases of being on a medication — starting, plateauing, maintaining, stopping
That list matters more than it might look. It’s a list of things researchers currently can’t reliably answer. The statement isn’t reporting a discovery; it’s naming what the field doesn’t yet know, and asking for the studies that would find out.
The discontinuation finding is the most concrete part
Not everything in the statement is a research gap — some of it is already established, and it’s worth sitting with. The statement points out that people who stop treatment after reaching a goal weight typically regain it, along with a worsening of the metabolic markers that had improved: blood pressure, cholesterol, blood sugar. There’s a more encouraging half to that finding too — research on transitioning to lower maintenance doses, or to a different medication, suggests substantial weight loss can be sustained without staying on the original regimen indefinitely. But the headline point stands: obesity medications currently behave like treatments for a chronic condition, not like a course you finish. That has practical implications for anyone deciding whether to start one, and it’s a big part of why our program is structured around ongoing licensed-provider review rather than a fixed end date.
What this doesn’t establish
It’s worth being precise about what a scientific statement is and isn’t. This is a synthesis and a research agenda, not a new clinical trial. It doesn’t report a study that measured these organ-specific outcomes and found a result — it’s the argument that someone should. If you see a company market “beyond the scale” results based on this statement, they’re citing a call for research, not a finding.
It’s also worth naming plainly: everything the statement reviews — the weight-loss data, the comorbidity reductions, the discontinuation research — comes from trials of manufactured, branded GLP-1 medications studied under FDA-regulated development programs. Compounded semaglutide and tirzepatide, the medications available through provider-guided telehealth programs like ours, are prepared by licensed pharmacies for individual patients and have not been through equivalent trials. They are not FDA-approved products. None of the six research priorities above have been studied for a compounded preparation specifically, and the statement doesn’t claim otherwise.
The statement also acknowledges its own limits. Dr. Drucker: “We need larger, longer, and more diverse studies, as well as greater use of real-world data to understand treatment outcomes.” Long-term safety data — what happens after five or ten years on these medications — remains genuinely incomplete for the entire drug class, branded or compounded.
Why this framing matters beyond academia
The statement specifically calls out sleep apnea as one of the health domains that a weight-loss percentage doesn’t capture. Two people can lose an identical amount of weight and see very different changes in their apnea-hypopnea index — the research on GLP-1s and sleep apnea already shows this, and it’s part of why a number on a scale was never a substitute for an actual sleep study. If you don’t know your AHI before treatment, you have no way to know whether it changed. The Happy Sleep program, delivered by Happy Sleep and offered through NoBsRx, exists for exactly that gap — measuring what a scale can’t.
The same logic applies to the GLP-1 side. A licensed provider’s independent review of your history and symptoms was never meant to be a scale check. It’s meant to catch the things a percentage doesn’t: whether treatment is appropriate for you at all, and whether it’s working in the ways that actually matter for your health. This statement is a group of specialists saying, formally, that the industry’s favorite number was always an incomplete answer to the question patients are actually asking.
This post is general information, not medical advice. It summarizes a professional society’s research agenda, not new clinical trial results, and it is not a claim about the outcome of any NoBsRx program. Compounded medications are not FDA-approved. Treatment is never guaranteed — eligibility, diagnosis, and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Talk to a licensed clinician about whether any treatment is appropriate for you.